Symbol="CUE"
AssetType="Common Stock"
Name="Cue Biopharma"
Description="Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biological drugs for the selective modulation of the human immune system to treat a variety of cancers, chronic infectious diseases, and autoimmune disorders. The company is headquartered in Cambridge, Massachusetts."
CIK="1645460"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="21 ERIE STREET, CAMBRIDGE, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="129103000"
EBITDA="-52093224"
PERatio="None"
PEGRatio="None"
BookValue="1.052"
DividendPerShare="0"
DividendYield="0"
EPS="-1.23"
RevenuePerShareTTM="0.044"
ProfitMargin="0"
OperatingMarginTTM="-29.52"
ReturnOnAssetsTTM="-0.418"
ReturnOnEquityTTM="-0.98"
RevenueTTM="1789200"
GrossProfitTTM="1245200"
DilutedEPSTTM="-1.23"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="52.15"
AnalystTargetPrice="10"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="13.03"
PriceToBookRatio="2.501"
EVToRevenue="9.35"
EVToEBITDA="-1.9"
Beta="1.982"
num_52WeekHigh="5.12"
num_52WeekLow="2.18"
num_50DayMovingAverage="3.798"
num_200DayMovingAverage="3.514"
SharesOutstanding="43178200"
DividendDate="None"
ExDividendDate="None"
symbol="CUE"
open="2.88"
high="3.04"
low="2.85"
price="2.99"
volume="268788.00"
latest_trading_day="2023-08-18"
previous_close="2.92"
change="0.07"
change_percent="2.3973%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="42"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="58"
Volume_recent_avg="405397"
Change_recent_avg="-0.03"
Delta_recent_avg="0.27"
Variance_recent_avg="0.13"
Change_ratio_recent_avg="-0.8"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="58"
Aroon_momentum_negative="42"
image_negative_thumbnail_id_1="493"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0112.jpeg"
image_negative_thumbnail_id_2="1148"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0181.jpeg"
image_neutral_thumbnail_id_1="544"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0055.jpeg"
image_neutral_thumbnail_id_2="526"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0073.jpeg"
image_positive_thumbnail_id_1="670"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0038.jpeg"
image_positive_thumbnail_id_2="988"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0150.jpeg"
image_professor_thumbnail_id_1="1171"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0005.jpeg"
image_professor_thumbnail_id_2="1202"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0036.jpeg"
